---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-056335"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:13:02.093617+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion reports Q3 net loss of $28.4M, advances diabetes and oncology pipeline

## Summary
- Net loss of $28.4M for Q3 2023 vs $22.9M in Q3 2022; cash of $199.5M as of Sep 30, 2023.
- COVALENT-111 expansion cleared; 84% of patients showed HbA1c reduction at Week 4; enrollment in ~200 type 2 diabetics.
- IND cleared for COVALENT-112 (BMF-219) in type 1 diabetes; enrollment of 150 adults expected to start in Q4 2023.
- Initial AML data: 2 CRs out of 5 patients with menin-dependent mutations at Dose Level 4; BMF-500 first patient dosed.
- Appointed Juan Pablo Frías, M.D., as Chief Medical Officer to oversee diabetes clinical development.

## SEC filing metadata
- accession: 0000950170-23-056335
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017023056335/0000950170-23-056335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017023056335/bmea-20231030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-056335
- JSON: https://secwatch.observer/filing/0000950170-23-056335.json
- Plain text: https://secwatch.observer/filing/0000950170-23-056335.txt

## Key facts
- Earnings Releases
  Biomea Fusion, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On October 30, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840439/000095017023056335/0000950170-23-056335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.